FDA 483 - Ursa Brown-Glaberman - December 19, 2025

An FDA inspection of Ursa Brown-Glaberman in Albuquerque, NM, identified a significant issue related to clinical trial conduct. The firm failed to promptly report serious adverse events (SAEs) to the study sponsor for multiple participants, indicating a lapse in adherence to protocol requirements for timely safety reporting.